


Express Mail Label N .: EV 3528205 US

Date of Deposit: October 21, 2002

Attorney Docket No. 15966-557 CIP2 (Cura 57 CIP2)

10-22-02

1647



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

APPLICANTS: Jeffers, et al.

SERIAL NUMBER: 09/817,814

EXAMINER: Christine Saoud

FILING DATE: March 26, 2001

ART UNIT: 1647

FOR: Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

#13
M.G.J.
10/29/02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Jeffers, [REDACTED]
U.S.S.N.: 09/817,814

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-557 CIP2 (Cura-57 CIP2).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: October 21, 2002

TRA 1724250v1

Express Mail Label: EV 138 5 US
Date of Deposit: October 21, 2002

Attorney Docket No.: 15966-557 CIP2 (Cura-57 CIP2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers, et al.
SERIAL NUMBER : 09/817,814 EXAMINER : Christine Saoud
FILING DATE : March 26, 2001 ART UNIT : 1647
FOR : Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same

BOX IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 page);
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References A2, A3, B3-B5 and C16, C17; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-557 CIP2 (Cura-57 CIP2). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: October 21, 2002